BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7854774)

  • 1. New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer.
    Locker GJ; Mader RM; Braun J; Sieder AE; Marosi C; Rainer H; Jakesz R; Steger GG
    Oncology; 1995; 52(2):140-4. PubMed ID: 7854774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
    Steger GG; Mader R; Derfler K; Moser K; Dittrich C
    Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer.
    Sliwowska I; Kopczyński Z; Grodecka-Gazdecka S
    Postepy Hig Med Dosw (Online); 2006; 60():295-9. PubMed ID: 16767053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
    Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L
    Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
    Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
    Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
    Plebani M; Basso D; Del Favero G; Ferrara C; Meggiato T; Fogar P; Mangano F; Ricciardi G; Burlina A
    Oncology; 1993; 50(6):436-40. PubMed ID: 8233283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
    van Dalen A
    Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
    Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
    Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
    Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
    Carpelan-Holmström M; Haglund C; Lundin J; Alfthan H; Stenman UH; Roberts PJ
    Br J Cancer; 1996 Sep; 74(6):925-9. PubMed ID: 8826859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma.
    Silver HK; Archibald BL; Ragaz J; Coldman AJ
    Cancer Res; 1991 Apr; 51(7):1904-9. PubMed ID: 2004374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
    Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
    Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
    Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological markers for metastatic breast cancer.
    Ng JS; Sturgeon CM; Seth J; Paterson GM; Roulston JE; Leonard RC
    Dis Markers; 1993 Dec; 11(5-6):217-23. PubMed ID: 8082311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.